.jpeg)
2026-04-20 04:21:47
Enfortumab vedotin (brand name Padcev) is the world's first Nectin-4-targeted antibody-drug conjugate (ADC) co-developed by Seagen and Astellas. It has been approved by the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with locally advanced or metastatic urothelial carcinoma.
2026-04-20 04:06:29
Urece (generic name: dotinurad) is a highly selective urate reabsorption inhibitor developed by Fuji Yakuhin, Japan. It has been approved in Japan, China, and other countries for the treatment of adult patients with gout and hyperuricemia.
2026-04-20 03:57:16
Mirvetuximab soravtansine (brand name Elahere) is the world's first folate receptor alpha (FRα)-targeted antibody-drug conjugate (ADC) developed by ImmunoGen, USA. It has received full approval from the FDA, EMA, and other global regulatory agencies for the treatment of adult patients with FRα-positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer.
2026-04-15 05:07:26
Mitotane, the sole approved drug for adrenocortical carcinoma (ACC), is reaffirmed as the preferred adjuvant therapy in the latest NCCN Guidelines 2026. This article dissects its mechanisms, dosing protocols, safety considerations, and international pricing trends, offering authoritative guidance for Hong Kong, Macau, and overseas patients.
2026-04-13 07:05:12
Anagrelide is a platelet-lowering agent used in essential thrombocythemia (ET). Learn about its indications, mechanism, potential side effects, and expert guidance for safe use in managing elevated platelet counts.
2026-04-13 06:40:50
Trodelvy is a breakthrough antibody-drug conjugate (ADC) targeting Trop-2, approved for metastatic triple-negative breast cancer (mTNBC), urothelial carcinoma, and other Trop-2 positive solid tumors. Learn about its mechanism, indications, safety, and global accessibility.
2026-04-13 04:04:58
A comprehensive overview of Azacitidine (Azacitidine) for Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML), and Chronic Myelomonocytic Leukemia (CMML). Learn about indications, legal purchase options, and essential precautions for patients seeking cross-border medication access.
2026-04-10 05:57:45
Odevixibat (Bylvay) is the first FDA-approved oral IBAT inhibitor for Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome. By reducing bile acid reabsorption, it lowers serum levels and alleviates liver damage, offering a novel therapy for pediatric and adult patients.
2026-04-10 05:37:39
Futibatinib is a selective FGFR1-4 kinase inhibitor targeting cholangiocarcinoma with FGFR alterations. By blocking oncogenic signaling, it offers a novel treatment option for patients with refractory disease, following genetic testing confirmation.
2026-04-10 05:05:56
Ibrutinib, a BTK inhibitor, targets mantle cell lymphoma, chronic lymphocytic leukemia, and other blood cancers by blocking the B-cell receptor pathway. Monotherapy or combination regimens improve outcomes, while managing risks such as bleeding and infections.
2026-04-10 04:56:03
Axitinib, a targeted therapy, demonstrates significant efficacy in advanced renal cell carcinoma (RCC). Combining with immunotherapy or as monotherapy, it offers innovative first-line and second-line treatment approaches, effectively prolonging survival and improving quality of life while managing potential side effects.
2026-04-09 05:56:04
Trametinib, an oral selective MEK1/2 inhibitor, in combination with dabrafenib revolutionizes treatment for BRAF-mutant melanoma, NSCLC, and rare cancers, offering targeted efficacy and manageable safety profile.
